Opinion|Videos|June 28, 2024
Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS
Key opinion leaders address various challenges linked to lower-risk myelodysplastic syndromes, with a focus on cytopenias.
Advertisement
Episodes in this series
- Dr Garcia-Manero to Dr Oliva: What present challenges exist for treating patients with lower-risk MDS? Do not take to transplant. Challenge for other cytopenias—no drug for this. Remission of low-risk disease.
Advertisement
Related to this article
Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.
An MD Anderson Cancer Center study identified a new link between immune cells and a copper-induced form of cell death called cuproptosis.
Early phase 2 data showed a median OS of 29.3 months with BPM31510 plus chemoradiation in an MGMT-unmethylated subgroup of treatment-naive glioblastoma.
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss evolving evidence-based decision-making across CSCC.
Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
2
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer
3
Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma
4
CAR T-Cell Engineering Produces Early Efficacy Signals in Glioblastoma
5